Navigation Links
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
Date:11/20/2008

BRIDGEWATER, N.J., Nov. 20 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States.

The application follows the completion of a multicenter, randomized Phase III study, ET743-OVA-301, one of the largest studies conducted in ROC, comparing the combination of trabectedin and DOXIL to DOXIL alone in 672 patients. The study showed that patients treated with the combination treatment had a statistically significant improvement in the primary endpoint of progression-free survival (PFS, or the length of time during and after treatment in which the disease does not progress) compared to patients treated with DOXIL alone.

"This is a significant milestone in the development of trabectedin, an agent with a novel mechanism of action that holds promise for patients with relapsed ovarian cancer," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/ Nephrology, Ortho Biotech Products, L.P. "We are confident in the strength of the data supporting the application and look forward to working with the FDA throughout the regulatory review process."

Relapsed ovarian cancer refers to epithelial carcinoma of the ovary that recurs after treatment. According to the National Cancer Institute (NCI), it is estimated that 21,650 women will be diagnosed with, and 15,520 women will die from ovarian cancer in the U.S. in 2008.

Trabectedin is being developed under a license from PharmaMar, and DOXIL is marketed by Ortho Biotech Products, L.P. in the U.S.

About the ET743-OVA-301 Study

Patients were enrolled at 124 centers in 21 countries. Per the study protocol, the data were evaluated by a blinded, independent radiology review and a blinded, independent oncology review. The trabectedin/DOXIL combination demonstrated a statistically significant improvement in PFS compared to DOXIL alone (median PFS 7.3 versus 5.8 months, respectively) and a statistically significant reduction of 21% in the risk of progression or death during the observation period in the independent review of patients with radiologically measurable disease (HR=0.79, 95% CI (0.65;0.96), p=0.0190). This result is consistent with the results of the independent oncology review that takes into account clinical as well as imaging data in the assessment of progression. In this review, there was a 28% risk reduction for disease progression or death with the trabectedin/DOXIL combination (HR=0.72, 95% CI (0.60; 0.88), p=0.0008).

Secondary endpoints included response rate, overall survival, and safety. A statistically significant increase in response rate was seen with the trabectedin and DOXIL combination (28%) compared to DOXIL alone (19%), as measured by the independent radiology review. A final protocol-specified survival analysis is planned after the occurrence of 520 events. The safety profile in the study was consistent with previous experience with trabectedin and DOXIL.

The most common adverse reactions (greater than or equal to 20%) for the trabectedin/DOXIL combination compared to DOXIL alone, respectively, were:

  • Hematological reactions including neutropenia (77% versus 38%, with febrile neutropenia occurring in 8% of the cases and sepsis in 1% of the cases), leucopenia (48% versus 26%), anemia (48% versus 25%) and thrombocytopenia (36% versus 8%);
  • Gastrointestinal reactions including nausea (74% versus 42%), vomiting (56% versus 30%) and diarrhea (26% versus 19%);
  • Liver enzyme (transaminase) elevations were more common in the combination arm, but were generally reversible and not associated with evidence of chronic liver damage or other clinical consequences. These included increased alanine aminotransferase (55% versus 9%) and increased aspartate aminotransferase (40% versus 10%); and
  • Fatigue (46% versus 36%).

Additionally, commonly associated DOXIL adverse events, such as hand-foot syndrome (HFS) and stomatitis, occurred in fewer patients receiving the combination compared to DOXIL alone (24% versus 54% and 20% versus 33%, respectively).

About Trabectedin

Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate ("sea squirt"). The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA, interfering with cell division and genetic transcription processes and DNA repair machinery. Trabectedin is currently in Phase III development in ovarian cancer and to expand its uses in sarcoma.

According to the licensing agreement, PharmaMar has rights to market the compound in Europe and Japan, while Ortho Biotech Products, L.P. has marketing rights for the product in the rest of the world.

About Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit www.orthobiotech.com.

Ortho Biotech Products, L.P. is a member of the Johnson & Johnson Family of Companies.

Forward-Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Orthopedic Oncology Fellowship Program at Mount Clemens Brings Highly Trained Surgeons to State
2. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
3. Dental Implants Effective for Orthodontic Treatment
4. Hanger Orthopedic Group, Inc. Receives Favorable New Code for WalkAide
5. Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education
6. Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association
7. Orthodontists Offer Sweet Incentives for Tricky Halloween Treats
8. Hanger Orthopedic Group, Inc. Exceeds Estimates on a 10% Sales Increase and a 28% EPS Increase to $0.23 for the Third Quarter 2008
9. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
10. Hanger Orthopedic Group, Inc. Announces Underwritten Public Offering by Shareholder
11. Amy Street, Certified Prosthetist and Orthotist, Joins BridgePoint Medical Partner, Charlotte Orthotic and Prosthetic Center (COPC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: